BioLineRx Ltd - Company Profile
Powered by
All the data and insights you need on BioLineRx Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date BioLineRx Ltd Strategy Report
- Understand BioLineRx Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on BioLineRx Ltd patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
US20240131111A1 | Application | Composition of bl-8040 | A61K38/12; A61P35/00 | April 25, 2024 |
ES2965461T3 | Grant | Inhibidor de cxcr4 para el tratamiento del cáncer | A61K31/497; A61K31/635; A61K38/12; A61K38/16; A61K38/162; A61K38/195; A61K45/06; A61P31/18; A61P35/00; C12N15/1132; C12N2310/141; C12Q1/6886; C12Q2600/106; C12Q2600/158; C12Q2600/178; G01N2333/7158; G01N2500/10; G01N2800/28; G01N33/57484; G01N33/6863 | April 15, 2024 |
EP4117704A4 | Search Report | Cxcr4-hemmer zur behandlung von akutem atemnotsyndrom und virusinfektionen | A61K2300/00; A61K31/13; A61K31/395; A61K31/522; A61K31/662; A61K31/7056; A61K31/706; A61K38/10; A61K38/21; A61K45/06; A61P11/00; A61P11/16; A61P31/14; C07K14/52; C07K7/64; Y02A50/30 | April 10, 2024 |
IL282317B2 | Grant | Treatment of metastatic pancreatic adenocarcinoma | A61K2039/505; A61K2039/54; A61K2039/545; A61K2300/00; A61K31/4745; A61K31/513; A61K31/519; A61K38/10; A61K38/12; A61K39/3955; A61K45/06; A61P1/18; A61P35/00; A61P35/04; C07K16/2818 | April 01, 2024 |
US20240092827A1 | Application | Process for manufacturing peptide | C07K1/20; C07K1/042; C07K1/10 | March 21, 2024 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer